An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions

Journal of Experimental Medicine

Volumn 190, Issue 5, 1999, Pages 651-667

  Anichini, Andrea ^a   Molla, Alessandra ^a   Mortarini, Roberta ^a   Tragni, Gabrina ^a   Bersani, Ilaria ^a   Di Nicola, Massimo ^a   Gianni, Alessandro M ^a   Pilotti, Silvana ^a   Dunbar, Rod ^b   Cerundolo, Vincenzo ^b   Parmiani, Giorgio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cytotoxic T lymphocytes; Melan A Mart 1; Melanoma; Peptide specific CTL precursors; Tumor escape

Indexed keywords

HLA ANTIGEN CLASS 1; PEPTIDE;

ADULT; ANTIGEN PRESENTING CELL; ARTICLE; CELL LINE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; MALE; MELANOCYTE; MELANOMA; MEMORY CELL; METASTASIS; PRIORITY JOURNAL; TUMOR ESCAPE;

ADULT; AGED; AMINO ACID SEQUENCE; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; FEMALE; HLA ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGIC MEMORY; IMMUNOLOGIC SURVEILLANCE; LYMPHOCYTE ACTIVATION; MALE; MELANOCYTES; MELANOMA; MIDDLE AGED; MONOPHENOL MONOOXYGENASE; NEOPLASM PROTEINS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0032844479     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.190.5.651     Document Type: Article

References (40)

1. Clark, W.H., Jr., D.E. Elder, D. Guerry IV, L.E. Braitman, B.J. Trock, D. Schultz, M. Synnestvedt, and A.C. Halpern. 1989. Model predicting survival in stage I melanoma based on tumor progression. J. Natl. Cancer Inst. 81:1893-1904.
2. Mihm, M., C. Clemente, and N. Cascinelli. 1996. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab. Invest. 74:43-47.
3. Sensi, M.L., and G. Parmiani. 1995. Analysis of TCR usage in human tumors: a new tool for assessing tumor-specific immune responses. Immunol. Today. 16:588-595.
4. Rivoltini, L., Y. Kawakami, K. Sakaguchi, S. Southwood, A. Sette, P.F. Robbins, F.M. Marincola, M.L. Salgaller, J.R. Yannelli, E. Appella, et al. 1995. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in-vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol. 154:2257-2265.
5. Salgaller, M.L., A. Afshar, F.M. Marincola, L. Rivoltini, Y. Kawakami, and S.A. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in-vitro with synthetic peptides. Cancer Res. 55:4972-4979.
6. Anichini, A., R. Mortarini, C. Maccalli, P. Squarcina, K. Fleischhauer, L. Mascheroni, and G. Parmiani. 1996. Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A*0201-restricted immune repertoire to melanoma. J. Immunol. 156:208-217.
7. Marincola, F.M., L. Rivoltini, M.L. Salgaller, M. Player, and S.A. Rosenberg. 1996. Differential anti-Mart-1/Melan-A CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison with healthy donors: evidence of in-vivo priming by tumor cells. J. Immunother. 19:266-277.
8. Balch, C.M., D.S. Reintgen, J.M. Kirkwood, A. Houghton, L. Peters, and K.K. Ang. 1997. Cutaneous melanoma. In Cancer Principles & Practice of Oncology, 5th Ed. V.T. De Vita, S. Hellman, and S.A. Rosenberg, editors. Lippincott-Raven. 1947-1994.
9. Boon, T., and P. van der Bruggen. 1996. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 83:725-729.
10. Rosenberg, S.A. 1999. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity. 10:281-287.
11. Kawakami, Y., S. Eliyahu, K. Sakaguchi, P.F. Robbins, L. Rivoltini, J.R. Yannelli, E. Appella, and S.A. Rosenberg. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180:347-352.
12. Marincola, F.M., Y. Hijazi, P. Fetsch, M.L. Salgaller, L. Rivoltini, J. Cormier, T.B. Simonis, P.H. Duray, M. Herlyn, Y. Kawakami, et al. 1996. Analysis of expression of the melanoma associated antigens Mart-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. J. Immunother. 19: 192-205.
13. Russo, C., A.K. Ng, M.A. Pellegrino, and S. Ferrone. 1983. The monoclonal antibody CR11-351 discriminates HLA-A2 variants identified by T cells. Immunogenetics. 18:23-35.
14. Morrison, J., J. Elvin, F. Latron, F. Gotch, R. Moots, J.L. Strominger, and A. McMichael. 1992. Identification of the nonamer peptide from influenza A matrix protein and the role of pockets of HLA-A2 in its recognition by cytotoxic T lymphocytes. Eur. J. Immunol. 22:903-907.
15. Wolfel, T., A. Van Pel, V. Brichard, J. Schneider, B. Seliger, K.H.M. zum Buschenfelde, and T. Boon. 1994. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol. 24:759-764.
16. 27-35-specific CTL from PBL of melanoma patients with low frequency of CTL precursors. Cancer Res. 57:5534-5541.
17. Nijman, H.W., J.G.A. Houbiers, S.H. Van der Burg, M.P.M. Vierboom, P. Kenemans, W.M. Kast, and C.J. Melief. 1993. Characterization of cytotoxic T lymphocyte epitopes of a self protein, p53, and a non-self protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides. J. Immunother. 14:121-126.
18. Ogg, G.S., P.R. Dunbar, P. Romero, J.L. Chen, and V. Cerundolo. 1998. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J. Exp. Med. 188:1203-1208.
19. Valmori, D., J.F. Fontaneau, C.M. Lizana, N. Gervois, D. Lienard, D. Rimoldi, V. Jongeneel, F. Jotereau, J.C. Cerottini, and P. Romero. 1998. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/Mart-1 immunodominant peptide analogues. J. Immunol. 160:1750-1758.
20. Busam, K.J., and A.A. Jungbluth. 1999. Melan-A, a new melanocytic differentiation marker. Adv. Anal. Pathol. 6:12-18.
21. Mazzocchi, A., F. Belli, L. Mascheroni, C. Vegetti, G. Parmiani, and A. Anichini. 1994. Frequency of cytotoxic T lymphocyte precursors (CTLp) interacting with autologous tumor via the T-cell receptor: limiting dilution analysis of specific CTLp in peripheral blood and tumor-invaded lymph nodes of melanoma patients. Int. J. Cancer. 58:330-339.
22. + melanoma patients have a memory phenotype. Int. J. Cancer. 78: 699-706.
23. + cytotoxic T-lymphocyte precursors specific for herpes simplex viruses in persons with genital herpes. J. Virol. 70:8165-8168.
24. Cerny, A., J.G. McHutchinson, C. Pasquinelli, M.E. Brown, M.A. Brothers, B. Grabscheid, P. Fowler, M. Houghton, and F.V. Chisari. 1995. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides. J. Clin. Invest. 95:521-530.
25. - T lymphocytes of non-infected donors contain cytotoxic T lymphocyte precursors at high frequency. Int. Immunol. 6:1739-1749.
26. Albert, M.L., B. Sauter, and N. Bhardwaj. 1998. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 392:86-89.
27. Gabrilovich, D.I., H.L. Chen, K.R. Girgis, H.T. Cunningham, G.M. Meny, S. Nadaf, D. Kavanaugh, and D.P. Carbone. 1996. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2:1096-1103.
28. 27-35). J. Exp. Med. 184:647-657.
29. 27-35). Cancer Res. 58:2433-2439.
30. McMichael, A.J., and C.A.O. Callaghan. 1998. A new look at T cells. J. Exp. Med. 187:1367-1371.
31. + T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Clin. Cancer Res. 3:221-226.
32. Dunbar, P.R., G.S. Ogg, J. Chen, N. Rust, P. van der Bruggen, and V. Cerundolo. 1998. Direct isolation, phenotyping and cloning of low frequency antigen-specific CTL from peripheral blood. Curr. Biol. 8:413-416.
33. + memory T cells. J. Exp. Med. 186:859-865.
34. Lehner, P.J., E.G. Wang, P.A. Moss, S. Williams, K. Platt, S.M. Friedman, J.I. Bell, and L.K. Borysiewicz. 1995. Human HLA-A0201-restricted cytotoxic T lymphocyte recognition of influenza A is dominated by T cells bearing the Vβ 17 gene segment. J. Exp. Med. 181:79-91.
35. Romero, P., P.R. Dunbar, D. Valmori, M. Pittet, G.S. Ogg, D. Rimoldi, J.L. Chen, D. Lienard, J.C. Cerottini, and V. Cerundolo. 1998. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med. 188:1641-1650.
36. Rosenberg, S.A., J.C. Yang, D.J. Schwartzentruber, P. Hwu, F.M. Marincola, S.L. Topalian, N.P. Restifo, M.E. Dudley, S.L. Schwarz, P.J. Spiess, et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:321-327.
37. Nestle, F.O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf. 1998. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat. Med. 4:328-332.
38. Ferrone, S., and F. Marincola. 1995. Loss of HLA-class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol. Today. 16:487-494.
39. Zea, A.H., B.D. Cutri, D.L. Longo, W.G. Alvord, S.L. Strobl, H. Mizoguchi, S.P. Creekmore, J.J. O'Shea, G.C. Powers, W.J. Urba, et al. 1995. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin. Cancer Res. 1:1327-1335.
40. Guarini, A., L. Riera, A. Cignetti, L. Montacchini, M. Massaia, and R. Foa. 1997. Transfer of interleukin-2 gene into human cancer cells induces specific antitumor recognition and restores the expression of CD3/T-cell receptor associated signal transduction molecules. Blood. 89:212-218.